Press release: invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023
APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing platform technology to manufacture Cbl-b silenced PBMCs and deliver treatment in under 24 hours Data...
April 18, 2023
No Comments
Press release: invIOs to present at Biotech Showcase
Vienna, Austria, 14 December 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter Llewellyn-Davies will present a corporate update during...
December 14, 2022
No Comments
Press release: invIOs presents positive patient data from ongoing Phase 1b trial of APN401 cell therapy in advanced solid tumors at SITC 2022
Poster presentation shows treatment with APN401, an autologous cell therapy product targeting the master immune checkpoint Cbl-b, resulted in stabilization of disease for more than six months in a heavily...
November 9, 2022
No Comments
Press release: APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01
Administration of aerosolized APN01 shown to be safe and well tolerated at all dose levels, with no adverse events above Grade 2 Investigators recommend further development of inhaled APN01, which…
November 3, 2022
No Comments
Press release: invIOs to present data from clinical stage Cbl-b program at SITC 2022
Vienna, Austria, 18 October 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that two abstracts on its clinical stage lead program, APN401,…
October 18, 2022
No Comments
Press release: invIOs to present at upcoming industry and investor conferences
Vienna, Austria, 11 October 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces its participation at three upcoming industry and investor conferences: BIO-Europe, Inv€$tival...
October 11, 2022
No Comments
Press release: APEIRON shareholders approve new group structure
geared towards enabling innovation and growth invIOs becomes fully separate entity focused on advancing its unique EPiC cell therapy platform and clinical-stage immuno-oncology pipeline Vienna, Austria, 26 April 2022. APEIRON...
April 26, 2022
No Comments
Press release: invIOs to present at upcoming conferences
Vienna, Austria, 03 February 2022: invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, today announced the participation at three upcoming investor conferences, the BIO CEO &...
February 3, 2022
No Comments
